This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n7http://www.drugs.com/ppa/
n26http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/pubchem-substance/
n21http://www.rxlist.com/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/iuphar/
n25http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/guide-to-pharmacology/
n10http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/patent/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/chemspider/
n22http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB06809/identifier/wikipedia/
n29http://linked.opendata.cz/resource/atc/
n28http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06809
rdf:type
n3:Drug
n3:description
Plerixafor is a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin lymphoma and multiple myeloma for the purpose of stimulating the immune system. These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells that were destroyed by chemotherapy. Plerixafor has orphan drug status in the United States and European Union; it was approved by the U.S. Food and Drug Administration on December 15, 2008.
n3:dosage
n4:271B5512-363D-11E5-9242-09173F13E4C5 n4:271B5511-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Uy GL, Rettig MP, Cashen AF: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18847313 # Fricker SP: A novel CXCR4 antagonist for hematopoietic stem cell mobilization. Expert Opin Investig Drugs. 2008 Nov;17(11):1749-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18922110 # DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G: Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720-6. Epub 2009 Apr 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19363221 # Stewart DA, Smith C, MacFarland R, Calandra G: Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19135941 # Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R: FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology. 2010;78(3-4):282-8. Epub 2010 Jun 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20530974 # Choi HY, Yong CS, Yoo BK: Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Pharmacother. 2010 Jan;44(1):117-26. Epub 2009 Dec 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20009003 # Keating GM: Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21861545
n3:group
approved
n3:halfLife
Terminal elimination half-life, NHL patients: 4.4 hours; Terminal elimination half-life, MM patients: 5.6 hours; Terminal elimination half-life, Hodgkin's lymphoma patients: 3.5 hours; Distribution half-life: 0.3 hours
n3:indication
Used in combination with granulocyte-colony stimulating factor (G-CSF, filgrastim) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
owl:sameAs
n25:DB06809 n27:DB06809
dcterms:title
Plerixafor
adms:identifier
n10:58468-0140-1 n11:65015 n13:844 n14:D08971 n15:DB06809 n16:844 n17:120346 n18:58531 n19:PA165958410 n20:Plerixafor n26:99443297
n3:mechanismOfAction
Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered. Filgrastim, a granulocyte-colony stimulating factor, is added to enhance CD34+ cell mobilization, thus increasing the yield of stem cells- an important determinant of graft adequacy.
n3:patent
n8:6%2C987%2C102 n8:7%2C897%2C590 n8:RE42152
n3:routeOfElimination
0.24 mg/kg, healthy subjects: ~70% of the parent drug is excreted in urine in the first 24 hours.
n3:synonym
LM3100 Mozobil AMD3100
n3:toxicity
LD50, mouse, SC: 16.3 mg/kg; LD50, rat, SC: >50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg
n3:volumeOfDistribution
0.3 L/kg
n3:proteinBinding
58%
n22:hasConcept
n23:M0544665
foaf:page
n7:plerixafor.html n21:mozobil-drug.htm
n3:IUPAC-Name
n5:271B5517-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B551D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B551C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5519-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B551A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B551B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B552C-363D-11E5-9242-09173F13E4C5 n5:271B5515-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5516-363D-11E5-9242-09173F13E4C5 n5:271B5513-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5514-363D-11E5-9242-09173F13E4C5
n3:pKa
n5:271B552E-363D-11E5-9242-09173F13E4C5
n28:hasATCCode
n29:L03AX16
n3:H-Bond-Acceptor-Count
n5:271B5523-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5524-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B551E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B551F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5521-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5520-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5522-363D-11E5-9242-09173F13E4C5
n3:absorption
Pharmacokinetic profile follows a two-compartment model with first-order absorption. A median peak plasma concentration of 0.24 mg/kg of plerixafor occurred 30-60 minutes after subcutaneous dose.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
110078-46-1
n3:category
n3:clearance
Total plasma clearance: 4.38 L/h; Renal clearance: 3.15 L/h
n3:Bioavailability
n5:271B5528-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B552A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B552B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B552D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5527-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5526-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5529-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5518-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5525-363D-11E5-9242-09173F13E4C5